Meal patterns and macronutrient intake after peripheral and PVN injections of the alpha 2-receptor antagonist idazoxan.
Studies with idazoxan (IDA), a specific alpha 2-noradrenergic receptor antagonist, demonstrate effects on feeding behavior opposite to those observed with norepinephrine in the paraventricular nucleus (PVN) and peripheral injection of the alpha 2 agonist clonidine. Administration of IDA, both intraperitoneally (IP) and into the PVN at the onset of the nocturnal feeding cycle, caused a dose-related, selective suppression of carbohydrate intake 90 min after injection. To characterize further the impact of this antagonist on macronutrient intake, we examined in IDA-injected animals the macrostructure of feeding using computer-assisted analyses of meal patterns. Both IP and PVN administration of IDA produced a selective suppression of carbohydrate intake, primarily during the first meal of the feeding cycle. This effect occurred through significant reductions in meal size, diet composition, feeding time, and feeding rate for this nutrient. Idazoxan administration into the PVN continued to decrease carbohydrate intake in the next two meals and reduced the satiating impact of this nutrient. In contrast to this immediate change in carbohydrate intake, PVN IDA reduced protein intake after a latency of 4 h. although fat intake was suppressed only after a latency of 7 h. An increase in total meal number and a decrease in the average meal size across the 12-h dark cycle were seen after PVN IDA administration. These results, showing effects of peripheral and PVN-injected IDA on carbohydrate intake, suggest a possible physiological role of endogenous PVN alpha 2-noradrenergic receptors in modulating natural patterns of carbohydrate feeding at the onset of the dark period.
Alexander
J T
JT
Rockefeller University, New York, NY 10021.
Cheung
W K
WK
Dietz
C B
CB
Leibowitz
S F
SF
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D004040:Dietary Carbohydrates / Q000008:administration & dosage*; D004041:Dietary Fats / Q000008:administration & dosage; D004044:Dietary Proteins / Q000008:administration & dosage; D004146:Dioxanes / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D002149:Energy Intake / Q000187:drug effects / Q000502:physiology; D005247:Feeding Behavior / Q000187:drug effects* / Q000502:physiology; D005518:Food Preferences / Q000187:drug effects* / Q000502:physiology; D019329:Idazoxan; D008297:Male; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011941:Receptors, Adrenergic / Q000187:drug effects* / Q000502:physiology
D000317:Adrenergic alpha-Antagonists; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D004044:Dietary Proteins; D004146:Dioxanes; D011941:Receptors, Adrenergic; D019329:Idazoxan